Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Avid Bioservices.

    Client Virtual Booth

    AVID BIOSERVICES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Avid Bioservices
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2642 Michelle Drive, Suite 200, Tustin, CA 92780
    Telephone
    Telephone
    714-508-6000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avidbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avid-bioservices
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab

    Details:

    This collaboration enhances commercial production efforts for lenzilumab in advance of potential filings for emergency use authorization (EUA) and subsequent Biologics License Application (BLA) later this year.


    Lead Product(s): Lenzilumab

    Therapeutic Area: Immunology Product Name: Humaneered

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Humanigen

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement February 03, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody

    Details:

    Mapp Biopharmaceutical has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phase of the project.


    Lead Product(s): Human monoclonal antiviral antibody

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Recipient: Mapp Biopharmaceutical

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership August 26, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine

    Details:

    Under terms of the agreement, Avid will provide Oragenics with analytical method development, process development and drug substance manufacturing services to support development of Oragenics’ novel SARS CoV-2 (COVID-19) spike protein vaccine candidate, Terra CoV-2.


    Lead Product(s): Terra CoV-2 vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Terra CoV-2

    Highest Development Status: UndisclosedProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Oragenics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement August 20, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001

    Details:

    Iovance Biotherapeutics has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein.


    Lead Product(s): IOV-3001

    Therapeutic Area: Oncology Product Name: IOV-3001

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Iovance Biotherapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement August 06, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search